Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Sees Significant Increase in Short Interest

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 8,114 shares, an increase of 381.3% from the May 14th total of 1,686 shares. Currently, 0.7% of the company’s shares are sold short. Based on an average daily volume of 14,113 shares, the short-interest ratio is presently 0.6 days.

Global X Genomics & Biotechnology ETF Price Performance

Shares of NASDAQ GNOM opened at $47.92 on Thursday. The company has a market cap of $53.67 million, a P/E ratio of -20.48 and a beta of 1.21. Global X Genomics & Biotechnology ETF has a 1 year low of $32.08 and a 1 year high of $51.42. The firm has a 50-day simple moving average of $46.31 and a two-hundred day simple moving average of $46.33.

Institutional Trading of Global X Genomics & Biotechnology ETF

Several institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its stake in Global X Genomics & Biotechnology ETF by 67.8% in the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after purchasing an additional 48,394 shares during the last quarter. Wealth Management Partners LLC bought a new stake in shares of Global X Genomics & Biotechnology ETF during the first quarter valued at approximately $244,000. Creative Financial Designs Inc. ADV raised its stake in shares of Global X Genomics & Biotechnology ETF by 4.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after acquiring an additional 481 shares in the last quarter. U.S. Capital Wealth Advisors LLC bought a new stake in shares of Global X Genomics & Biotechnology ETF during the fourth quarter valued at approximately $575,000. Finally, IFP Advisors Inc raised its stake in shares of Global X Genomics & Biotechnology ETF by 20.8% during the third quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after acquiring an additional 489 shares in the last quarter. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.